180 Wealth Advisors LLC Sells 88 Shares of Amgen Inc. (NASDAQ:AMGN)

180 Wealth Advisors LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,966 shares of the medical research company’s stock after selling 88 shares during the period. 180 Wealth Advisors LLC’s holdings in Amgen were worth $2,337,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new stake in Amgen in the third quarter worth about $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter worth about $29,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen during the second quarter valued at approximately $30,000. Matrix Trust Co purchased a new stake in Amgen in the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory purchased a new position in Amgen during the 3rd quarter valued at approximately $56,000. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on AMGN shares. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target on the stock. Leerink Partners decreased their target price on shares of Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They set a “peer perform” rating for the company. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Price Performance

Amgen stock opened at $270.19 on Tuesday. The business has a 50-day moving average of $278.16 and a 200-day moving average of $308.35. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The firm has a market capitalization of $145.24 billion, a P/E ratio of 34.60, a PEG ratio of 2.91 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.96 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.52%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.